Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04633187
Registration number
NCT04633187
Ethics application status
Date submitted
11/11/2020
Date registered
18/11/2020
Date last updated
13/09/2023
Titles & IDs
Public title
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Who Are Infected With Acute Respiratory Syncytial Virus (RSV) of the Upper Respiratory Tract
Query!
Scientific title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Query!
Secondary ID [1]
0
0
EDP 938-103
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RSVTx
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - EDP-938
Treatment: Drugs - Placebo
Experimental: EDP-938 -
Placebo Comparator: Placebo -
Treatment: Drugs: EDP-938
EDP-938 800mg
Dose adjustments will be made for subjects taking azole antifungals.
Treatment: Drugs: Placebo
Subjects will take EDP-938 matching placebo tablets once a day orally for 21 days
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of subjects who develop Lower Respiratory Tract (LRTC) complication
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Day 1 through Day 28
Query!
Secondary outcome [1]
0
0
Change from baseline in RSV RNA viral load
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Day 1 through Day 49
Query!
Secondary outcome [2]
0
0
Proportion of Subjects Progressing to Respiratory Failure (of any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or all-cause mortality
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Day 1 through Day 49
Query!
Secondary outcome [3]
0
0
Safety as measured by frequency of adverse events (AEs)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Day 1 through Day 49
Query!
Secondary outcome [4]
0
0
Plasma PK Concentrations of EDP-938
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Day 0 through Day 21
Query!
Eligibility
Key inclusion criteria
- Received an autologous HCT (within 6 months of signing ICF) or an allogeneic HCT (any
time) using any conditioning regimen
- Absolute lymphocyte count (ALC) <500 cells/ µL in allogeneic HCT recipients. Absolute
lymphocyte count (ALC) <300 cells/ µL in autologous HCT recipients.
- Laboratory confirmed RSV diagnosis from a respiratory sample obtained within 3 days
before signing the ICF.
- New onset of at least one of the following respiratory symptoms within 3 days before
signing the ICF: nasopharyngeal discharge, nasopharyngeal congestion, sneezing, sinus
congestion, sore throat, hoarseness, earache, cough, shortness of breath, respiratory
wheeze, or worsening of one of these symptoms if present chronically (associated with
a previously existing diagnosis [eg, chronic rhinorrhea, chronic lung disease]) in the
3 days before signing the ICF or at Screening.
- No evidence of new abnormalities consistent with LRTI on a chest imaging (chest x-ray
and/or computed tomography) performed in the 2 days before signing the ICF or at the
Screening visit if there is no chest X-ray and/or computed tomography available in the
2 days before signing the ICF.
- Oxygen saturation >95% on room air.
- A woman of childbearing potential who is sexually active with a male must agree to use
two effective methods of contraception from the date of Screening until 30 days after
her last dose of study drug.
- A male subject who has not had a vasectomy and is sexually active with a woman of
childbearing potential must agree to use effective contraception from the date of
Screening to 90 days after his last dose of study drug.
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Admitted to the hospital primarily for a lower respiratory tract disease of any cause
as determined by the Investigator.
- Known to be concurrently infected with other respiratory viruses (eg, severe acute
respiratory syndrome coronavirus 2 [SARS-CoV-2] or other coronavirus, influenza,
parainfluenza, human rhinovirus, adenovirus, human metapneumovirus) within 7 days
before signing the ICF, as determined by local testing.
- Clinically significant viremia, bacteremia, or fungemia, or bacterial or fungal
pneumonia within 2 weeks before signing the ICF that has not been adequately treated,
as determined by the Investigator.
- Known positive human immunodeficiency virus (HIV).
- Any clinical manifestation resulting in QT prolongation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/07/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/04/2024
Query!
Actual
Query!
Sample size
Target
200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Westmead Hospital - Westmead
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Texas
Query!
Country [3]
0
0
Argentina
Query!
State/province [3]
0
0
Buenos Aires
Query!
Country [4]
0
0
Argentina
Query!
State/province [4]
0
0
Ciudad Autónoma De BuenosAires
Query!
Country [5]
0
0
Argentina
Query!
State/province [5]
0
0
Cordoba
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Antwerpen
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Brussels
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
La Louvière
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
Distrito Federal
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Rio Grande Do Sul
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Sao Paulo
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Ontario
Query!
Country [13]
0
0
China
Query!
State/province [13]
0
0
Hong Kong
Query!
Country [14]
0
0
Colombia
Query!
State/province [14]
0
0
Valle Del Cauca
Query!
Country [15]
0
0
Colombia
Query!
State/province [15]
0
0
Medellín
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Alpes-Maritimes
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Maine-et-Loire
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Nord
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Caen
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Paris
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Pierre-Bénite
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Baden-Württemberg
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Rheinland-Pfalz
Query!
Country [24]
0
0
Greece
Query!
State/province [24]
0
0
Athens
Query!
Country [25]
0
0
Israel
Query!
State/province [25]
0
0
Haifa
Query!
Country [26]
0
0
Israel
Query!
State/province [26]
0
0
Jerusalem
Query!
Country [27]
0
0
Israel
Query!
State/province [27]
0
0
Ramat Gan
Query!
Country [28]
0
0
Israel
Query!
State/province [28]
0
0
Tel Aviv
Query!
Country [29]
0
0
Italy
Query!
State/province [29]
0
0
Lombardia
Query!
Country [30]
0
0
Italy
Query!
State/province [30]
0
0
Marche
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Piemonte
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Veneto
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Firenze
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Roma
Query!
Country [35]
0
0
Korea, Republic of
Query!
State/province [35]
0
0
Daejeon
Query!
Country [36]
0
0
Korea, Republic of
Query!
State/province [36]
0
0
Seoul
Query!
Country [37]
0
0
Korea, Republic of
Query!
State/province [37]
0
0
Ulsan
Query!
Country [38]
0
0
Mexico
Query!
State/province [38]
0
0
Mexico City
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Slaskie
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Gdansk
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Szczecin
Query!
Country [42]
0
0
South Africa
Query!
State/province [42]
0
0
Gauteng
Query!
Country [43]
0
0
South Africa
Query!
State/province [43]
0
0
Johannesburg
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Baleares
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Barcelona
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Caceres
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Murcia
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Granada
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Madrid
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Málaga
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Sevilla
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Valencia
Query!
Country [53]
0
0
Taiwan
Query!
State/province [53]
0
0
Changhua
Query!
Country [54]
0
0
Taiwan
Query!
State/province [54]
0
0
Taipei City
Query!
Country [55]
0
0
Turkey
Query!
State/province [55]
0
0
Izmir
Query!
Country [56]
0
0
Turkey
Query!
State/province [56]
0
0
Tekirdag
Query!
Country [57]
0
0
Turkey
Query!
State/province [57]
0
0
Samsun
Query!
Country [58]
0
0
United Kingdom
Query!
State/province [58]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Enanta Pharmaceuticals, Inc
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study
evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and
symptoms of URTI.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04633187
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Enanta Pharmaceuticals, Inc
Query!
Address
0
0
Enanta Pharmaceuticals, Inc
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Enanta Pharmaceuticals, Inc
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
(617) 607-0800
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04633187
Download to PDF